Clinical-Microbiomics A/S: Financial statements 2020
CVR: 37230634
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Clinical-Microbiomics A/S (CVR 37230634) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 17,023,992 and a net result of DKK 816,247 compared with DKK 106,977 the year before. That is an increase of 29.3% compared with the year before. Equity in the 2020 report amounted to DKK -3,330,334. The company had 19 employees in the financial year.
- Gross Profit
- DKK 17,023,992
- Profit/Loss
- DKK 816,247
- Equity
- DKK -3,330,334
- Total Assets
- DKK 12,542,882
- Employees
- 19
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 17 mio. | 816 t. | -3.3 mio. | 19 |
| 2019 | - | 13.2 mio. | 107 t. | -4.1 mio. | 16 |
| 2018 | - | 8.5 mio. | -483 t. | -4.3 mio. | 12 |
| 2017 | - | 1.4 mio. | -4.4 mio. | -3.8 mio. | 9 |
Official annual report
How creditworthy is Clinical-Microbiomics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Clinical-Microbiomics A/S has published its annual report for 2019. Gross profit came to DKK 13,163,250, and the net result was DKK 106,977.
About Clinical-Microbiomics A/S
Clinical-Microbiomics A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Clinical-Microbiomics ApS. The management consists of Anders Christian Neto de Sousa Grøn. The board consists of Manoj Nirmal Dadlani (chair), Bruce Harvey Grant, Caroline Popper and Isabelle Valerie de Cremoux. The company's owners include MANJIN ApS, VENDLER ApS and Health For Life Capital II Prima S.C.A. RAIF. The company has 32 employees (2026). In 2025, the company reported a gross profit of EUR 2,831,000 and a net result of EUR -2,586,000 compared with EUR -4,328,000 the year before. Equity in the 2025 report amounted to EUR 85,447,000.